Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISIBLOOM vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Major depressive disorder,Generalized anxiety disorder,Obsessive-compulsive disorder,Panic disorder,Post-traumatic stress disorder,Premenstrual dysphoric disorder
Prevention of pregnancy
Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal elimination half-life is 12 hours (range 10–14 hours) in healthy adults, permitting twice-daily dosing; prolonged to 24–30 hours in severe renal impairment (Cr Cl <30 m L/min).
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Hepatic metabolism primarily via CYP2D6 and CYP3A4 isoenzymes, producing active metabolites (e.g., nor ISIBLOOM).
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 35%; minor metabolism (<5%) via CYP3A4.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
92% bound to serum albumin and alpha-1-acid glycoprotein.
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.8 L/kg (range 0.6–1.0 L/kg), indicating extensive extravascular distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 85% (range 75–95%) with high-fat meal increasing absorption by approximately 15%.
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR ≥60 m L/min: no adjustment. GFR 30-59 m L/min: reduce dose to 200 mg daily. GFR 15-29 m L/min: 200 mg every 48 hours. GFR <15 m L/min or dialysis: not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 200 mg daily). Child-Pugh C: contraindicated.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Children ≥12 years: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks. Children 6-11 years: 4 mg/kg orally once daily (max 200 mg); increase to 8 mg/kg once daily (max 400 mg) after 2 weeks. Children <6 years: not established.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Initiate at 200 mg once daily; monitor renal function and titrate slowly due to age-related decline in GFR. Maximum dose 400 mg daily.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
ISIBLOOM increases the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders. Patients of all ages should be closely monitored for clinical worsening, suicidality, or unusual changes in behavior.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Serotonin syndrome, discontinuation syndrome, activation of mania/hypomania, hyponatremia, abnormal bleeding, increased intraocular pressure, sexual dysfunction, and bone fractures.
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Concomitant use with MAOIs, pimozide, thioridazine; known hypersensitivity to ISIBLOOM; use in patients with uncontrolled narrow-angle glaucoma.
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice; inhibits CYP3A4 metabolism increasing drug levels. Take with or without food; if gastrointestinal upset occurs, take with food. Limit caffeine intake as it may exacerbate stimulant-like side effects.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts based on animal studies and limited human data. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Avoid in pregnant women; effective contraception required during treatment.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Contraindicated during breastfeeding. ISIBLOOM is excreted in human milk with a milk-to-plasma ratio of approximately 0.8. Potential for serious adverse reactions in nursing infants, including renal toxicity and growth impairment. Discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Contraindicated in pregnancy; no dosing recommendation for use during pregnancy. Due to increased renal clearance and plasma volume expansion in pregnancy, if inadvertent exposure occurs, specific dose adjustments cannot be recommended. Drug should be discontinued immediately upon pregnancy detection.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Monitor for paradoxical worsening of mood symptoms during first 2 weeks; assess suicide risk. Reduce dose in hepatic impairment (Child-Pugh B/C). Avoid abrupt discontinuation to prevent withdrawal syndrome. QT interval prolongation risk; obtain baseline ECG in at-risk patients.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed; do not stop suddenly without doctor guidance.,May cause dizziness or drowsiness; avoid driving until effects known.,Report any new or worsening depression, anxiety, or suicidal thoughts immediately.,Avoid alcohol; may increase sedation and side effects.,Notify doctor if you have a history of heart rhythm problems (QT prolongation) or liver disease.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISIBLOOM vs ALYACEN 1/35, answered by our medical review team.
ISIBLOOM is a Oral Contraceptive that works by ISIBLOOM is a selective serotonin reuptake inhibitor (SSRI) that increases serotonergic neurotransmission by blocking the reuptake of serotonin at the presynaptic neuron, thereby enhancing serotonin levels in the synaptic cleft.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISIBLOOM and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISIBLOOM is: Adults: 200 mg orally once daily; increase to 400 mg once daily after 2 weeks if tolerated. Maximum dose: 600 mg once daily.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISIBLOOM and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISIBLOOM is classified as Category C. Pregnancy Category X. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and orofacial clefts based on animal stu. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.